Clinical Trials Logo

Blood Loss, Surgical clinical trials

View clinical trials related to Blood Loss, Surgical.

Filter by:
  • Enrolling by invitation  
  • Page 1

NCT ID: NCT06078501 Enrolling by invitation - Clinical trials for Blood Loss, Surgical

MisOpRostol Effect on Second Trimester Abortion Blood Loss

MORESTABL
Start date: February 8, 2024
Phase: Phase 3
Study type: Interventional

Although serious complications from second trimester abortion are rare hemorrhage is the most common cause of procedural abortion related morbidity and mortality. Misoprostol is a prostaglandin E1 analogue that is used by 75% of clinicians prior to procedural abortion for the purpose of cervical preparation. Misoprostol is also known to decrease blood loss in first trimester abortion and is used to treat postpartum hemorrhage, however the effect of preprocedural misoprostol on procedural blood loss is not well described. We will conduct a double blinded placebo-controlled gestational age stratified superiority trial of those undergoing procedural abortion between 18 and 23 weeks gestation at Stanford Health care. Participants will be randomized to either 400mcg buccal misoprostol or placebo on the day of the procedure. A quantified blood loss (QBL) will be measured during the procedure and participants will complete a survey to assess symptoms. Our primary outcome is quantified blood loss. Secondary outcomes include clinical interventions to manage excess bleeding, total procedure time, provider reported experience, patient reported experience.

NCT ID: NCT05474027 Enrolling by invitation - Clinical trials for Blood Loss, Surgical

Reducing Hypotensive Anesthesia Use With TXA During Orthognathic Surgery

Start date: November 11, 2022
Phase: Phase 4
Study type: Interventional

This prospective study will analyze the need for deliberate hypotensive anesthesia (DHA) during orthognathic surgery when tranexamic acid (TXA) is administered. DHA has been proven to be effective although it comes with multiple risks related to organ hypoperfusion including kidney injury, stroke, and cardiac ischemia. Therefore, it may be potentially safer for patients to avoid deliberate hypotensive anesthesia if TXA alone adequately controls blood loss and provides adequate surgical site visualization.